Chris Smyth, PhD


Developing New Clinical Endpoints for Immuno-Oncology Studies

February 23, 2017

Drug developers are using surrogate endpoints to monitor the effectiveness of immunotherapies, taking into account the differences between immunotherapy and traditional treatments.

Harnessing CRISPR-Cas9 within Oncology Clinical Research

September 29, 2016

Gene-editing technology has the ability to give oncology researchers an effective treatment option in the fight against cancer. CRISPR-Cas9 is such a technology that is currently being used to study genes in cancer cells.